Ghent University Academic Bibliography

Advanced

TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models

Thomas Naert UGent, Tom Van Nieuwenhuysen UGent and Kris Vleminckx UGent (2017) GENESIS. 55(1-2).
abstract
The targeted nuclease revolution (TALENs, CRISPR/Cas9) now allows Xenopus researchers to rapidly generate custom on-demand genetic knockout models. These novel methods to perform reverse genetics are unprecedented and are fueling a wide array of human disease models within the aquatic diploid model organism Xenopus tropicalis (X. tropicalis). This emerging technology review focuses on the tools to rapidly generate genetically engineered X. tropicalis models (GEXM), with a focus on establishment of genuine genetic and clinically relevant cancer models. We believe that due to particular advantageous characteristics, outlined within this review, GEXM will become a valuable alternative animal model for modeling human cancer. Furthermore, we provide perspectives of how GEXM will be used as a platform for elucidation of novel therapeutic targets and for preclinical drug validation. Finally, we also discuss some future prospects on how the recent expansions and adaptations of the CRISPR/Cas9 toolbox might influence and push forward X. tropicalis cancer research.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
EPITHELIAL-MESENCHYMAL TRANSITIONS, NEURAL CREST DEVELOPMENT, IN-VIVO, SONIC HEDGEHOG, ZINC-FINGER, DEVELOPMENTAL PATHWAYS, MUTATION DETECTION, SIGNALING PATHWAY, NUCLEASE ACTIVITY, EFFICIENT DESIGN, desmoid tumors, drug assessment, familial adenomatous polyposis, genome, editing, retinoblastoma, target identification
journal title
GENESIS
Genesis
volume
55
issue
1-2
article number
e23005
pages
10 pages
Web of Science type
Review
Web of Science id
000393958400013
ISSN
1526-954X
DOI
10.1002/dvg.23005
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
8514540
handle
http://hdl.handle.net/1854/LU-8514540
date created
2017-03-16 13:18:17
date last changed
2017-07-26 12:38:30
@article{8514540,
  abstract     = {The targeted nuclease revolution (TALENs, CRISPR/Cas9) now allows Xenopus researchers to rapidly generate custom on-demand genetic knockout models. These novel methods to perform reverse genetics are unprecedented and are fueling a wide array of human disease models within the aquatic diploid model organism Xenopus tropicalis (X. tropicalis). This emerging technology review focuses on the tools to rapidly generate genetically engineered X. tropicalis models (GEXM), with a focus on establishment of genuine genetic and clinically relevant cancer models. We believe that due to particular advantageous characteristics, outlined within this review, GEXM will become a valuable alternative animal model for modeling human cancer. Furthermore, we provide perspectives of how GEXM will be used as a platform for elucidation of novel therapeutic targets and for preclinical drug validation. Finally, we also discuss some future prospects on how the recent expansions and adaptations of the CRISPR/Cas9 toolbox might influence and push forward X. tropicalis cancer research.},
  articleno    = {e23005},
  author       = {Naert, Thomas and Van Nieuwenhuysen, Tom and Vleminckx, Kris},
  issn         = {1526-954X},
  journal      = {GENESIS},
  keyword      = {EPITHELIAL-MESENCHYMAL TRANSITIONS,NEURAL CREST DEVELOPMENT,IN-VIVO,SONIC HEDGEHOG,ZINC-FINGER,DEVELOPMENTAL PATHWAYS,MUTATION DETECTION,SIGNALING PATHWAY,NUCLEASE ACTIVITY,EFFICIENT DESIGN,desmoid tumors,drug assessment,familial adenomatous polyposis,genome,editing,retinoblastoma,target identification},
  language     = {eng},
  number       = {1-2},
  pages        = {10},
  title        = {TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models},
  url          = {http://dx.doi.org/10.1002/dvg.23005},
  volume       = {55},
  year         = {2017},
}

Chicago
Naert, Thomas, Tom Van Nieuwenhuysen, and Kris Vleminckx. 2017. “TALENs and CRISPR/Cas9 Fuel Genetically Engineered Clinically Relevant Xenopus Tropicalis Tumor Models.” Genesis 55 (1-2).
APA
Naert, T., Van Nieuwenhuysen, T., & Vleminckx, K. (2017). TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models. GENESIS, 55(1-2).
Vancouver
1.
Naert T, Van Nieuwenhuysen T, Vleminckx K. TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models. GENESIS. 2017;55(1-2).
MLA
Naert, Thomas, Tom Van Nieuwenhuysen, and Kris Vleminckx. “TALENs and CRISPR/Cas9 Fuel Genetically Engineered Clinically Relevant Xenopus Tropicalis Tumor Models.” GENESIS 55.1-2 (2017): n. pag. Print.